Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Teva Pharmaceuticals Found Liable in the Opioid Crisis
A New York jury found Teva Pharmaceuticals liable for contributing to the opioid crisis, marking a significant verdict among numerous lawsuits. Teva plans to appeal, disputing the lack of evidence linking its actions to harm. The case highlights the widespread legal battles against drug companies over opioid-related damages, with settlements reaching billions aimed at combating the epidemic.
Tapping into the drug discovery potential of AI
Evotec and Exscientia used AI to develop an anticancer molecule in 8 months, a process traditionally taking 4-5 years. Exscientia's AI platform accelerates drug discovery, leading to partnerships and significant funding. AI's role in drug discovery is expanding, with companies like Recursion and BenevolentAI leveraging AI for innovative treatments and collaborations with pharma giants.
J&J's new cancer drug leads a growing pipeline of dual-targeting treatments
The FDA approved Johnson & Johnson's Rybrevant, a bispecific antibody for treating a specific mutation in non-small cell lung cancer. Bispecific antibodies, targeting two proteins simultaneously, are emerging as a promising treatment for various cancers, including lymphoma, leukemia, and multiple myeloma, with several drugs in advanced clinical trials.
Recent Developments in Biosimilars: Legal Settlements, Launches, and Legislative Efforts
Recent developments in biosimilars include Biocon Biologics and Sandoz launching biosimilar competitors, legal settlements affecting biosimilar launches, and legislative efforts to increase biosimilar access. Key events involve adalimumab, ustekinumab, and aflibercept biosimilars, with companies like Amgen, Johnson & Johnson, and Regeneron at the center of legal and market activities.
NeuClone gibt präklinische Ergebnisse von Biosimilar-Kandidaten für Stelara® (Ustekinumab) bekannt
NeuClone announced positive preclinical results for its Stelara® biosimilar, confirming structural integrity via X-ray crystallography. Developed with Serum Institute of India, it's set for Phase I trials in 2019. Stelara®, a monoclonal antibody, treats diseases like plaque psoriasis and Crohn's disease. NeuClone focuses on biosimilar development using its NeuMAX® platform.
The Indian companies battling drug-resistant superbugs
Indian biotech start-up Bugworks, supported by CARB-X, aims to develop new antibiotics against superbugs amidst India's severe drug-resistance crisis. Despite financial hurdles, India's government and companies are pushing for solutions, with Bugworks and others nearing clinical trials. India's large patient base and pharmaceutical industry position it as a key player in combating antimicrobial resistance globally.
Neurotrophic Keratitis Market | Global Analysis Report 2027
The article provides a comprehensive analysis of the global neurotrophic keratitis market, including market segmentation, treatment types (drugs and surgical interventions), stages, and regional forecasts from 2017 to 2027. It highlights key industry developments, pipeline analysis, and competitive landscape, featuring major companies like Dompe farmaceutici S.p.A., Allergan, and others.
Prucalopride in the treatment of chronic constipation
Prucalopride 2 mg significantly improved bowel function in chronic constipation patients from the Asia-Pacific region over 12 weeks, with 33.3% achieving ≥3 spontaneous complete bowel movements per week vs 10.3% on placebo (P < 0.001). It was safe, well-tolerated, with common adverse events being diarrhea, nausea, abdominal pain, and headache.
Xarelto okayed by FDA for treating atrial fibrillation
The FDA approved Xarelto, a next-gen blood thinner, for atrial fibrillation treatment, offering an alternative to warfarin. Xarelto, effective once daily, blocks clotting protein factor Xa, similar in stroke prevention to warfarin but with a boxed warning against abrupt discontinuation due to stroke risk.
CAR-T Cell Therapy Market - Market Size, Forecasts, Trials
CAR-T cell therapy, a groundbreaking immunotherapy, modifies patient T-cells to target and destroy cancer cells, acting as 'living drugs.' With 11 products commercialized, including 7 FDA-approved, the therapy shows promise in treating blood cancers. Challenges include expanding to solid tumors, reducing 'vein-to-vein' time, and improving reimbursement. The industry is advancing through gene-transfer techniques, partnerships, and 'on-off' switches in CAR-T cells to enhance efficacy and safety.
© Copyright 2025. All Rights Reserved by MedPath